Improving Adherence and Outcomes by Artificial Intelligence-Adapted Text Messages

NCT ID: NCT02454660

Last Updated: 2017-04-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

49 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-05-31

Study Completion Date

2016-11-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Uncontrolled hypertension is a major cause of morbidity and mortality and many patients fail to take their antihypertensive medication as prescribed. The investigators propose to use artificial intelligence (AI) to allow short message service (SMS or text messages) interventions to adapt to patients' adherence needs and substantially improve medication taking. The aims of the study are to: (1) develop AI methods for adaptive decision-making in human-centered environments and demonstrate the feasibility of the resulting AI-enhanced SMS medication adherence intervention, (2) demonstrate that the intervention can "learn" by adapting the SMS message stream according to patients' medication taking over time, and (3) examine potential intervention impact as measured by improvements in medication adherence and systolic blood pressures. The investigators will recruit 100 patients with uncontrolled hypertension and antihypertensive medication non-adherence. Adherence and other covariates will be measured via surveys at baseline, 3- and 6 months; blood pressures will be measured at baseline and 6 months. Participants will be given an electronic pill-bottle adherence monitor. Participants will receive SMS messages designed to motivate antihypertensive medication adherence. Message content and frequency will adapt automatically using AI algorithms designed to automatically optimize expected pill bottle opening. For Aim 1, the first 25 patients will be enrolled to develop and test alternative RL algorithms and fine-tune the system parameters. For Aim 2, the investigators will examine changes in the probability distribution over message-types and compare that distribution with patients' reasons for non-adherence reported at baseline. For Aim 3, the investigators will examine changes in self-reported medication non-adherence and blood pressure and automatically-reported pill bottle openings. This pilot study will establish the feasibility and potential impact of this novel approach to mobile health messaging for self-management support. The results will be used to support an R01 application for a larger and more definitive trial of intervention impacts.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Self-management of chronic conditions involves complex behaviors, and patients vary in their adherence to these behaviors. The focus of this proposal is medication adherence because patients' failure to take their medications as prescribed is a major cause of excess morbidity and mortality and increased health care costs. Studies suggest that 33-50% of patients do not take their medications properly, contributing to nearly 100,000 premature deaths each year and $290 billion in health care costs. Adherence to antihypertensive medications is of particular importance in its own right, and hypertension can serve as an important tracer condition to better understand and improve medication adherence more generally. Uncontrolled hypertension is a major cause of stroke, coronary heart disease, heart failure and mortality, and medication non-adherence is a major cause of uncontrolled hypertension. For example, in a one-year study of \~5,000 hypertensive patients, most patients took their medications only intermittently with half of patients eventually discontinuing their medications against medical advise.

Improving medication adherence requires addressing multiple challenges because patients typically have a variety of reasons for not taking their medication as prescribed, such as beliefs about their disease and its treatment, organizational challenges, and cost barriers. Moreover, as patients' regimens, health status, and social context change over time, adherence support interventions need to adapt, but most services lack the flexibility to do so.

Mobile health (mHealth) services such as patient text messaging or SMS have shown some promise in improving medication adherence. However, since almost all mHealth services are based on simplistic, deterministic protocols, these interventions lack the capacity to meet patients' complex changing needs. As a consequence, these rudimentary systems have demonstrated only modest effects that tend to decrease over time. The investigators propose to apply artificial intelligence (AI) methods, specifically Reinforcement Learning (one type of AI), to develop a model medication adherence system that can automatically adapt SMS communication to improve individual medication taking.

The proposed project is the result of a new multidisciplinary collaboration between UM experts from the College of Pharmacy, College of Engineering, and School of Medicine. Our long-term goal is to improve health outcomes using artificial intelligence (AI) enhanced mobile health tools. The objective in the proposed pilot study is to develop a Reinforcement Learning-based mHealth program focused on medication adherence among patients with poorly controlled hypertension. Our central hypotheses are that a SMS system that uses Reinforcement Learning (RL) will: be acceptable to patients, adapt to hypertension patients' unique adherence-related needs and preferences and changes in these needs over time, and improve medication adherence and blood pressure control. The specific aims are:

1. Develop RL methods for adaptive decision-making in human-centered environments and demonstrate the feasibility of the resulting RL-based adaptive SMS medication adherence intervention,
2. Demonstrate "learning" by the RL-base adaptive system using data showing adaptation of the SMS message stream according to variation across patients and over time in the reasons for non-adherence, and
3. Examine the potential efficacy of the RL-based adaptive SMS intervention with respect to improvements in medication adherence and systolic blood pressure.

The results of this pilot project will include a novel AI/RL technology and evidence regarding its real-world use based on experience with a sample of adults with poorly controlled hypertension. These results will be used to support an R01 application for a larger and more definitive study of the intervention's impact on patients' health and long-term adherence behaviors. Over the longer term, this AI-enhanced mHealth self-management support infrastructure and unprecedented collaboration between investigators in Pharmacy, Medicine, and Computer Science will lay the foundation for a larger program of NIH-funded research using similar AI approaches to addressing behavior change challenges in a large number of health and healthcare problems.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Medication Non-adherence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SMS (Text messaging)

This group will receive text messages during their entire enrollment period in the study.

Group Type EXPERIMENTAL

SMS (Text messages)

Intervention Type BEHAVIORAL

Up to 1 text message a day. The artificial agent will determine whether to send a message each day. If it sends a message, it will also determine which of five message types to send.

No SMS (No text messages)

This group will not receive text messages during their entire enrollment period in the study.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SMS (Text messages)

Up to 1 text message a day. The artificial agent will determine whether to send a message each day. If it sends a message, it will also determine which of five message types to send.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient must have Priority Health Care Health Insurance Coverage
* Patient must have PDC of \< 0.5 for anti-hypertensive medications

Exclusion Criteria

* No hypertension medicine currently taken
* Patient doesn't text message (no cell phone) in an average week
* No access to the internet
* Patient has heart failure which makes it difficult to catch breath and move around
* Patient uses artificial oxygen to breathe
* Patient is currently under treatment for cancer
* Patient currently has kidney disease that requires dialysis
* Patient self reports a mental health diagnosis (from a health professional)
* Patient reports having schizophrenia
* Patient reports currently being treated bipolar disorder or manic-depressive illness or schizophrenia
* Patients reports ever been diagnosed with dementia or Alzheimer's disease
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Agency for Healthcare Research and Quality (AHRQ)

FED

Sponsor Role collaborator

University of Michigan

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Karen Farris, PhD.

Charles R. Walgreen Professor of Pharmacy Administration

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Karen Farris, PhD

Role: PRINCIPAL_INVESTIGATOR

Univerity of Michigan, College of Pharmacy

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Michigan College of Pharmacy

Ann Arbor, Michigan, United States

Site Status

Spectrum Health

Grand Rapids, Michigan, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Lawn S, Schoo A. Supporting self-management of chronic health conditions: common approaches. Patient Educ Couns. 2010 Aug;80(2):205-11. doi: 10.1016/j.pec.2009.10.006.

Reference Type BACKGROUND
PMID: 19931372 (View on PubMed)

Coleman MT, Newton KS. Supporting self-management in patients with chronic illness. Am Fam Physician. 2005 Oct 15;72(8):1503-10.

Reference Type BACKGROUND
PMID: 16273817 (View on PubMed)

Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005 Aug 4;353(5):487-97. doi: 10.1056/NEJMra050100. No abstract available.

Reference Type BACKGROUND
PMID: 16079372 (View on PubMed)

NEHI. Thinking outside the pillbox: a system-wide approach to improving patient medication adherence for chronic disease. http://www.nehi.net/publications/44/thinking_outside_the_pillbox_a_systemwide_approach_to_improving_patient_medication_adherence_for_chronic_disease, Accessed 09 12 12

Reference Type BACKGROUND

Hill MN, Miller NH, Degeest S; American Society of Hypertension Writing Group; Materson BJ, Black HR, Izzo JL Jr, Oparil S, Weber MA. Adherence and persistence with taking medication to control high blood pressure. J Am Soc Hypertens. 2011 Jan-Feb;5(1):56-63. doi: 10.1016/j.jash.2011.01.001.

Reference Type BACKGROUND
PMID: 21320699 (View on PubMed)

Munger MA, Van Tassell BW, LaFleur J. Medication nonadherence: an unrecognized cardiovascular risk factor. MedGenMed. 2007 Sep 19;9(3):58.

Reference Type BACKGROUND
PMID: 18092064 (View on PubMed)

Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008 May 17;336(7653):1114-7. doi: 10.1136/bmj.39553.670231.25. Epub 2008 May 14.

Reference Type BACKGROUND
PMID: 18480115 (View on PubMed)

Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD000011. doi: 10.1002/14651858.CD000011.pub3.

Reference Type BACKGROUND
PMID: 18425859 (View on PubMed)

Marx G, Witte N, Himmel W, Kuhnel S, Simmenroth-Nayda A, Koschack J. Accepting the unacceptable: medication adherence and different types of action patterns among patients with high blood pressure. Patient Educ Couns. 2011 Dec;85(3):468-74. doi: 10.1016/j.pec.2011.04.011. Epub 2011 May 19.

Reference Type BACKGROUND
PMID: 21600724 (View on PubMed)

Sabate E - World Health Organization. Adherence to long-term therapies: evidence for action. 2003. http://apps.who.int/medicinedocs/en/d/Js4883e/, Accessed 09 12 12

Reference Type BACKGROUND

Elliott RA, Shinogle JA, Peele P, Bhosle M, Hughes DA. Understanding medication compliance and persistence from an economics perspective. Value Health. 2008 Jul-Aug;11(4):600-10. doi: 10.1111/j.1524-4733.2007.00304.x. Epub 2008 Jan 8.

Reference Type BACKGROUND
PMID: 18194403 (View on PubMed)

Vervloet M, Linn AJ, van Weert JC, de Bakker DH, Bouvy ML, van Dijk L. The effectiveness of interventions using electronic reminders to improve adherence to chronic medication: a systematic review of the literature. J Am Med Inform Assoc. 2012 Sep-Oct;19(5):696-704. doi: 10.1136/amiajnl-2011-000748. Epub 2012 Apr 25.

Reference Type BACKGROUND
PMID: 22534082 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1R21HS022336-01A1

Identifier Type: AHRQ

Identifier Source: org_study_id

View Link

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Mobile Health Management of Hypertension
NCT05856955 NOT_YET_RECRUITING NA
Text My Hypertension BP Meds NOLA
NCT05074173 COMPLETED NA
Behavioral Study to Control Blood Pressure
NCT01035554 COMPLETED PHASE2/PHASE3